Quick Answer
ZyVersa Therapeutics, Inc. reported Research And Development Expense of $1.11 million for the year ending 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -37.4% in Research And Development Expense from 2024 to 2025.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2022 to 2025), ZyVersa Therapeutics, Inc.'s Research And Development Expense has declined by 79.4%.
- Historical annual values: Fiscal year 2025: $1.11 million | Fiscal year 2024: $1.78 million | Fiscal year 2023: $3.21 million | Fiscal year 2022: $399.9 thousand | Fiscal year 2022: $5.41 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: